Search results for "Treatment compliance"
showing 5 items of 5 documents
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI…
2021
ROMEI, a prospective, observational study in patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib in real-world practice, assesses treatment adherence based on the 8-item Morisky Medication Adherence Scale (MMAS-8). Here, we present MMAS-8 results at week 24. Overall, 101 of 188 evaluable patients completed the questionnaire at every visit (full completers). Mean (±standard deviation) total MMAS-8 scores remained stable from week 4 to week 24 in the overall population (7.54 ± 0.77 and 7.67 ± 0.70, respectively) and full completers (7.53 ± 0.79 and 7.67 ± 0.73, respectively). Rates of low (MMAS-8 ˂6) or medium (MMAS-8 ≥ 6 to ˂8) adherence were 25–40% and 26–36%, respec…
Generally Antisocial Batterers with High Neuropsychological Deficits Present Lower Treatment Compliance and Higher Recidivism
2021
Objective: No studies have considered whether neuropsychological performance moderates the relationship between Holtzworth-Munroe and Stuart's intimate partner violence against women (IPVAW) offender typologies and treatment compliance and recidivism. Therefore, we first aimed to assess whether the typologies show differences in specific neuropsychological variables such as cognitive flexibility and emotion decoding processes. Second, we also assessed whether there are differences in treatment compliance and recidivism between the IPVAW offender typologies, based on their neuropsychological performance. Method: We administered a set of neuropsychological tests (e.g., Wisconsin card sorting …
Noninfectious uveitis: strategies to optimize treatment compliance and adherence.
2015
Noninfectious uveitis includes a heterogenous group of sight-threatening ocular and systemic disorders. Significant progress has been made in the treatment of noninfectious uveitis in recent years, particularly with regard to the effective use of corticosteroids and non-corticosteroid immunosuppressive drugs, including biologic agents. All of these therapeutic approaches are limited, however, by any given patient's ability to comply with and adhere to their prescribed treatment. In fact, compliance and adherence are among the most important patient-related determinants of treatment success. We discuss strategies to optimize compliance and adherence.
Treatment Compliance in the Long-Term Paranoid Schizophrenia Telemedicine Study
2017
Schizophrenia is a chronic disease with a relatively high relapse rate. Different methods are introduced to improve compliance of the patients treated by psychiatrists; among them, a new and promising attitude is telepsychiatry. The 12-month clinical study of the compliance in paranoid schizophrenia was performed on the group of 199 patients. Every patient in the study was given a smartphone with the preinstalled original telemedicine platform (Telemedicine MoneoPlatform). The telemedicine system recorded every confirmation of the drug intake, and according to that, the compliance was counted as the percent of the doses of medication confirmed in relation to the planned ones. In the first m…
Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study
2006
None of the available osteoporosis therapies have been shown to completely abolish the risk of fractures. In clinical practice, the outcome may be even poorer. In 880 patients prescribed with antiresorptives (alendronate, risedronate, and raloxifene) for >1 year, a fragility fracture was recorded in 8.9%/year of them. This incidence is considerably higher than that observed in randomized clinical trials, and it was significantly related to poor compliance and lack of supplementation with calcium and vitamin D. Introduction: Osteoporotic fracture is one of the most important public health concerns among the elderly. Currently available therapies have been shown to significantly decrease the …